These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19580427)

  • 21. Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.
    Gevensleben H; Göhring UJ; Büttner R; Heukamp LC; Kunz G; Dimpfl T; Jackisch C; Ortmann O; Albert US; Bender R; De Snoo F; Krijgsman O; Glas AM; Ergönenc YH; Vogel C; Dykgers A; Langwieder C; Rees M; Anzeneder T
    Int J Mol Med; 2010 Dec; 26(6):837-43. PubMed ID: 21042777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding tumor profiling and assessing treatment.
    Hyams DM
    Manag Care; 2008 Jul; 17(7 Suppl 7):4-8; discussion 17-8. PubMed ID: 19093336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    Cardoso F; van't Veer LJ; Bogaerts J; Slaets L; Viale G; Delaloge S; Pierga JY; Brain E; Causeret S; DeLorenzi M; Glas AM; Golfinopoulos V; Goulioti T; Knox S; Matos E; Meulemans B; Neijenhuis PA; Nitz U; Passalacqua R; Ravdin P; Rubio IT; Saghatchian M; Smilde TJ; Sotiriou C; Stork L; Straehle C; Thomas G; Thompson AM; van der Hoeven JM; Vuylsteke P; Bernards R; Tryfonidis K; Rutgers E; Piccart M;
    N Engl J Med; 2016 Aug; 375(8):717-29. PubMed ID: 27557300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
    Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
    Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The MINDACT trial: the first prospective clinical validation of a genomic tool.
    Cardoso F; Piccart-Gebhart M; Van't Veer L; Rutgers E;
    Mol Oncol; 2007 Dec; 1(3):246-51. PubMed ID: 19383299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
    Nicolini A; Ferrari P; Duffy MJ
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular markers of breast axillary lymph node metastasis.
    Cavalli LR
    Expert Rev Mol Diagn; 2009 Jul; 9(5):441-54. PubMed ID: 19580429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Gene expression based multigene prognostic and predictive tests in breast cancer].
    Pénzváltó Z; Mihály Z; Gyorffy B
    Magy Onkol; 2009 Dec; 53(4):351-9. PubMed ID: 20071307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.
    Retèl VP; Byng D; Linn SC; Jóźwiak K; Koffijberg H; Rutgers EJ; Cardoso F; Piccart MJ; Poncet C; Van't Veer LJ; van Harten WH
    Eur J Cancer; 2020 Sep; 137():193-203. PubMed ID: 32795875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic subtypes in choosing adjuvant therapy for breast cancer.
    Zelnak AB; O'Regan RM
    Oncology (Williston Park); 2013 Mar; 27(3):204-10. PubMed ID: 23687790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer.
    Groenendijk FH; Jager A; Cardoso F; van Deurzen CHM
    Breast; 2018 Apr; 38():125-131. PubMed ID: 29310037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression profiling of primary breast cancer.
    Rouzier R; Wagner P; Morandi P; Pusztai L
    Curr Oncol Rep; 2005 Jan; 7(1):38-44. PubMed ID: 15610685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective cost-effectiveness analysis of genomic profiling in breast cancer.
    Retèl VP; Joore MA; Drukker CA; Bueno-de-Mesquita JM; Knauer M; van Tinteren H; Linn SC; van Harten WH
    Eur J Cancer; 2013 Dec; 49(18):3773-9. PubMed ID: 23992641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equivalence of MammaPrint array types in clinical trials and diagnostics.
    Beumer I; Witteveen A; Delahaye L; Wehkamp D; Snel M; Dreezen C; Zheng J; Floore A; Brink G; Chan B; Linn S; Bernards R; van 't Veer L; Glas A
    Breast Cancer Res Treat; 2016 Apr; 156(2):279-87. PubMed ID: 27002507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.
    Chen E; Tong KB; Malin JL
    Am J Manag Care; 2010 Dec; 16(12):e333-42. PubMed ID: 21291290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
    Ma CX; Bose R; Ellis MJ
    Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.
    Mook S; Bonnefoi H; Pruneri G; Larsimont D; Jaskiewicz J; Sabadell MD; MacGrogan G; Van't Veer LJ; Cardoso F; Rutgers EJ
    Eur J Cancer; 2009 May; 45(7):1201-1208. PubMed ID: 19232484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profiling in breast cancer.
    Morris SR; Carey LA
    Curr Opin Oncol; 2007 Nov; 19(6):547-51. PubMed ID: 17906450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.